Skip to main content

Table 1 The characteristics of the included studies

From: Prediction of sepsis mortality using metabolite biomarkers in the blood: a meta-analysis of death-related pathways and prospective validation

PubMed ID

Patient no. (M/F)

Comparison groups (S vs NS)

Age (years, median range, or SD) (S vs NS)

Follow-up

SOFA (S vs NS)

APACHE II (S vs NS)

SAPS II (S vs NS)

Matrix

PMID12562829

102 (71/31)

S (n = 63) vs NS (n = 39)

53.8 (20–91) vs 54.9 (17–80)

30 days

N/A

N/A

N/A

Plasma

PMID23673400

30 (16/14)

S (n = 15) vs NS (n = 15)

78 (73–83) vs 79 (76–82)

90 days

N/A

59 (53–75) vs 76 (74–95)#

N/A

Plasma

PMID23884467

121 70/51)

S (n = 90) vs NS (n = 31)

56.4 ± 19.2 vs 68.8 ± 16.7

28 days

4.3 ± 2.7 vs 7.0 ± 3.6

15.0 ± 7.1 vs 22.8 ± 7.8

N/A

Plasma

PMID23884467

52* (34/18)

S (n = 34) vs NS (n = 18)

58.9 ± 18.1 vs 58.0 ± 18.8

28 days

4.3 ± 2.7 vs 5.0 ± 3.0

5.7 ± 5.8 vs 18.5 ± 7.9

N/A

Plasma

PMID23884467

61* (33/28)

S (n = 36) vs NS (n = 25)

54.8 ± 13.1 vs 58.7 ± 16.5

28 days

N/A

25.9 ± 6.7 vs 33.0 ± 9.8

N/A

Plasma

PMID24368342

8

S (n = 4) vs NS (n = 4)

61 (56–70)

N/A

11 (5–14)

22 (16–27)

N/A

Serum

PMID24498130

90 (39/51)

S (n = 60) vs NS (n = 30)

53 ± 14 vs 58 ± 15

28 days

N/A

23 ± 9 vs 30 ± 11

N/A

Plasma

PMID24498130

149* 68/81)

S (n = 115) vs NS (n = 34)

58 ± 17 vs 69 ± 16

28 days

N/A

15 ± 7 vs 23 ± 8

N/A

Plasma

PMID25553245

35 (30/5)

S (n = 26) vs NS (n = 9)

63 ± 18 vs 67 ± 15

48 h

10 ± 4 vs 13 ± 5

20 ± 8 vs 26 ± 6

N/A

Serum

PMID25849571

35 (25/10)

S (n = 20) vs NS (n = 15)

54 ± 23 vs 61 ± 21

28 days

7 ± 4 vs 10 ± 5

14 ± 7 vs 22 ± 8

N/A

Serum

PMID25887472

121 (70/51)

S (n = 90) vs NS (n = 31)

56.4 ± 19.2 vs 68.8 ± 16.7

28 days

4.3 ± 2.7 vs 7.0 ± 3.6

15.0 ± 7.1 vs 22.8 ± 7.8

N/A

Plasma

PMID25928796

16

S (n = 8) vs NS (n = 8)

63 (59.8–77)

N/A

10.5 (7–12.5)

25.5 (17.5–31.3)

N/A

Serum

PMID26847922

20 (13/7)

S (n = 9) vs NS (n = 11)

61.3 ± 15.2 vs 69.9 ± 12

90 days

10.5 ± 1.5 vs 12.1 ± 2

N/A

54.8 ± 17.9 vs 61.1 ± 9.4

Plasma

PMID27406941

58

S (n = 28) vs NS (n = 30)

N/A

28 days

N/A

N/A

N/A

Plasma

PMID27614981

50 (27/23)

S (n = 21) vs NS (n = 29)

63.8 ± 0.7 vs 65.6 ± 0.5

7 days

10.0 ± 0.8 vs 11.3 ± 0.9

N/A

54 ± 0.4 vs 68 ± 0.5

Serum

PMID27632672

22 (13/9)

S (n = 13) vs NS (n = 9)

60 (27–84) vs 60 (36–80)

7 days

N/A

22 (14–38) vs 31 (16–46)

N/A

Plasma

PMID28345042

36 (27/9)

S (n = 20) vs NS (n = 16)

52 ± 21.5 vs 58 ± 16.7

28 days

N/A

17 ± 4.9 vs 22 ± 10.2

N/A

Plasma

PMID28345042

121* (70/51)

S (n = 90) vs NS (n = 31)

56.4 ± 19.2 vs 68.8 ± 16.7

28 days

4.3 ± 2.7 vs 7.0 ± 3.6

15.0 ± 7.1 vs 22.8 ± 7.8

N/A

Plasma

PMID30379669

90 (54/36)

S (n = 69) vs NS (n = 21)

71.5 ± 15.4 vs 69.6 ± 12.9

28 days

8.3 ± 3.5 vs 10.9 ± 4.0

23.1 ± 7.7 vs 26.1 ± 8.6

N/A

Plasma

PMID31088568

70 (40/30)

S (n = 40) vs NS (n = 30)

68.5 ± 0.3 vs 72.1 ± 0.4

24 h

10.9 ± 0.1 vs 12.4 ± 0.1

N/A

N/A

Serum

PMID31088568

70* (40/30)

S (n = 40) vs NS (n = 30)

68.5 ± 0.3 vs 72.1 ± 0.4

24 h

10.9 ± 0.1 vs 12.4 ± 0.1

N/A

55.2 ± 0.4 vs 64.3 ± 0.6

Serum

  1. Abbreviations: S survivors, NS nonsurvivors, SOFA The Sequential Organ Failure Assessment, APACHE II Acute Physiology and Chronic Health Evaluation II, SAPS II Simplified Acute Physiology Score, N/A not available
  2. *Validation cohort in the same publication
  3. #APACHE III